PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers

Background: There has been evidence that Polybromo-1 (PBRM1) mutation was closely associated with immunotherapy response in clear cell renal cell carcinoma (ccRCC). However, it remains incompletely unclear whether PBRM1 mutations correlate with ICI response in pan-cancer. Methods: The clinical data...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Jiali, Cui, Yanan, Liang, Xiao, Xu, Jiali, Li, Jun, Chen, Yu, Zhang, Erbao, Guo, Renhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868445/
https://www.ncbi.nlm.nih.gov/pubmed/36699446
http://dx.doi.org/10.3389/fgene.2022.1066347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868445/
https://www.ncbi.nlm.nih.gov/pubmed/36699446
http://dx.doi.org/10.3389/fgene.2022.1066347

Ejemplares similares